Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Brian A Jonas

Showing results (1-10 of 98) with videos related to

Pageof 10
Sort By:
Science Translational Medicine|March 10, 2017
From MDS/AML to iPSC and back againBrian A Jonas
Science Translational Medicine|July 14, 2017
On the origin of relapse in AMLBrian A Jonas
Science Translational Medicine|April 21, 2017
Combination of an oncolytic virus with PD-L1 blockade keeps cancer in checkBrian A Jonas
Science Translational Medicine|June 2, 2017
A new therapeutic target for myelofibrosis is cause for GliBrian A Jonas
Cancers|July 27, 2022
Clinical Impact of Measurable Residual Disease in Acute Myeloid LeukemiaTali Azenkot, Brian A Jonas
Core Evidence|May 24, 2019
Enasidenib in the treatment of relapsed/refractory acute myeloid leukemia: an evidence-based review of its place in therapyMaria Galkin, Brian A Jonas
Best Practice & Research. Clinical Haematology|February 10, 2015
MDS prognostic scoring systems – past, present, and futureBrian A Jonas, Peter L Greenberg
Oncotargets and Therapy|April 28, 2022
Targeting <i>TP53</i>-Mutated Acute Myeloid Leukemia: Research and Clinical DevelopmentsEric M Granowicz, Brian A Jonas
The Journal of Biological Chemistry|October 20, 2004
SMRT and N-CoR corepressors are regulated by distinct kinase signaling pathwaysBrian A Jonas, Martin L Privalsky
Blood Advances|August 13, 2024
This differentiation block will not stand, man: ivosidenib for MDSRyan J Beechinor, Brian A Jonas
Pageof 10

Showing results (1-10 of 98) with videos related to

Sort By:
Pageof 10
Science Translational Medicine|March 10, 2017
From MDS/AML to iPSC and back againBrian A Jonas
Science Translational Medicine|July 14, 2017
On the origin of relapse in AMLBrian A Jonas
Science Translational Medicine|April 21, 2017
Combination of an oncolytic virus with PD-L1 blockade keeps cancer in checkBrian A Jonas
Science Translational Medicine|June 2, 2017
A new therapeutic target for myelofibrosis is cause for GliBrian A Jonas
Cancers|July 27, 2022
Clinical Impact of Measurable Residual Disease in Acute Myeloid LeukemiaTali Azenkot, Brian A Jonas
Core Evidence|May 24, 2019
Enasidenib in the treatment of relapsed/refractory acute myeloid leukemia: an evidence-based review of its place in therapyMaria Galkin, Brian A Jonas
Best Practice & Research. Clinical Haematology|February 10, 2015
MDS prognostic scoring systems – past, present, and futureBrian A Jonas, Peter L Greenberg
Oncotargets and Therapy|April 28, 2022
Targeting <i>TP53</i>-Mutated Acute Myeloid Leukemia: Research and Clinical DevelopmentsEric M Granowicz, Brian A Jonas
The Journal of Biological Chemistry|October 20, 2004
SMRT and N-CoR corepressors are regulated by distinct kinase signaling pathwaysBrian A Jonas, Martin L Privalsky
Blood Advances|August 13, 2024
This differentiation block will not stand, man: ivosidenib for MDSRyan J Beechinor, Brian A Jonas
Pageof 10